Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERBOT: First-line trastuzumab, gemcitabine, cisplatin and nivolumab in advanced HER2-positive biliary tract cancer
KCT0008250Phase 2Not yet recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, gemcitabine, cisplatin, nivolumab in biliary cancer, sponsored by Ono Pharmaceutical. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0008250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008250.